International Journal of Artificial Organs最新文献

{"title":"Therapeutic effects of Huangqi Jixueteng decoction combined with erythropoietin on iron metabolism in in patients with renal anemia.","authors":"Shanzhai Wei, Yilai Zhang, Kangchun Xu, Man Wang","doi":"10.1177/03913988261474704","DOIUrl":"https://doi.org/10.1177/03913988261474704","url":null,"abstract":"<p><strong>Objective: </strong>This study investigated the therapeutic effects of Huangqi Jixueteng Decoction (HJD) combined with erythropoietin on iron metabolism in patients with renal anemia undergoing maintenance hemodialysis.</p><p><strong>Methods: </strong>Sixty patients with renal anemia receiving maintenance hemodialysis were randomly assigned to a Control Group (CG) treated with erythropoietin alone and an Observation Group (OG) treated with erythropoietin plus HJD. Changes in anemia-related indicators (red blood cell (RBC) count, hematocrit (HCT), hemoglobin (Hb)), inflammatory markers (tumor necrosis factor-α (TNF-α), C-reactive protein (CRP)), iron metabolism parameters (serum ferritin (SF), serum iron (SI), total iron-binding capacity (TIBC), transferrin saturation (TSAT)), and renal and hepatic function indicators (blood urea nitrogen (BUN), serum creatinine (Scr), alanine transaminase (ALT), aspartate transaminase (AST)) were compared between groups. Adverse drug reactions were also monitored.</p><p><strong>Results: </strong>Baseline values showed no significant differences between groups (<i>p</i> > 0.05). Post-treatment, RBC, HCT, and Hb levels increased significantly in both groups (<i>p</i> < 0.05), with greater improvement in the OG (<i>p</i> < 0.05). Inflammatory markers declined in both groups, with CRP and TNF-α levels significantly lower in the OG compared with the CG (<i>p</i> < 0.05). Indicators of iron metabolism (SF, SI, TIBC, TSAT) improved significantly in both groups (<i>p</i> < 0.05), with superior responses in the OG (<i>p</i> < 0.05). Renal and hepatic function indexes (BUN, Scr, AST) decreased post-treatment in both groups, with lower levels in the OG (<i>p</i> < 0.05). No significant differences were observed in adverse reactions such as dizziness, headache, or low-grade fever (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>The addition of Huangqi Jixueteng Decoction to erythropoietin therapy effectively enhances hematologic parameters, mitigates microinflammation, optimizes iron metabolism, and improves renal function in patients with dialysis-associated renal anemia. This integrative regimen appears safe and well tolerated, offering potential advantages for clinical management of renal anemia.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261474704"},"PeriodicalIF":1.6,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148880306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulation of dialysate temperature and its impact on post-dialysis fatigue and thermal comfort: A pre-post interventional study.","authors":"Gülay Turgay, Banu Çevik, Sultan Kav, Mustafa Gülşen, Işılay İnanoğlu, Semiha Kaya, Cihat Burak Sayın","doi":"10.1177/03913988261479989","DOIUrl":"https://doi.org/10.1177/03913988261479989","url":null,"abstract":"<p><strong>Background: </strong>Post-dialysis fatigue is a frequent and burdensome symptom in patients undergoing maintenance hemodialysis. While intradialytic symptoms are commonly monitored in clinical practice, symptoms emerging after dialysis and affecting post-dialysis recovery are often less systematically addressed. This study evaluated the effects of a reduced dialysate temperature on post-dialysis fatigue and thermal comfort.</p><p><strong>Methods: </strong>This single-group pre-post interventional study was conducted between May and June 2025 at a dialysis center. Of the 220 screened patients, 130 met the eligibility criteria after the predefined clinical exclusions. Patients with Post-Dialysis Fatigue Scale scores ⩾28 were included in the intervention phase (<i>n</i> = 57). The dialysate temperature was reduced from 36.5°C to 36.0°C for three consecutive sessions. Thermal comfort was assessed using a numerical visual analog scale. Data were analyzed using repeated-measures ANOVA, correlation, and regression analyses.</p><p><strong>Results: </strong>Post-dialysis fatigue significantly decreased after the intervention (<i>F</i> = 25.82, <i>p</i> < 0.001; <i>d</i>_z = 0.91). Changes in systolic blood pressure independently predicted fatigue improvement (β = -0.557, <i>p</i> = 0.019). Thermal comfort remained stable during the intervention.</p><p><strong>Conclusion: </strong>Reducing the dialysate temperature may be a feasible approach to alleviate post-dialysis fatigue without compromising thermal comfort.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261479989"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric intracorporeal LVAD support in the transition from HVAD to HeartMate 3.","authors":"Sedat Karaca, Osman Nuri Tuncer, Ümit Kahraman, Dilek Erdinli, Eser Doğan, Zulal Ulger Tutar, Cagatay Engin, Yuksel Atay, Tahir Yagdi, Mustafa Ozbaran","doi":"10.1177/03913988261480648","DOIUrl":"https://doi.org/10.1177/03913988261480648","url":null,"abstract":"<p><strong>Background: </strong>The withdrawal of the HeartWare HVAD required pediatric mechanical circulatory support programs to transition to alternative durable intracorporeal devices. We evaluated our single-center experience across the HVAD and HeartMate 3 (HM3) eras.</p><p><strong>Methods: </strong>We retrospectively reviewed all pediatric patients who underwent primary durable intracorporeal LVAD implantation between January 2012 and December 2024. Clinical characteristics, perioperative outcomes, survival on support, bridge-to-transplantation, and device-related adverse events were compared.</p><p><strong>Results: </strong>Thirty-four patients were included: 22 received HVAD and 12 received HM3. Baseline characteristics were generally comparable. Cardiopulmonary bypass time was significantly longer in the HM3 group (<i>p</i> < 0.001). Median support duration was longer with HVAD (1002 vs 838 days; <i>p</i> = 0.304). Survival on LVAD support did not differ between groups (log-rank <i>p</i> = 0.375). Pump thrombosis (40.9% vs 0%; <i>p</i> = 0.013) and ischemic stroke (27.3% vs 0%; <i>p</i> = 0.069) occurred only in HVAD recipients, whereas infectious complications were comparable between groups.</p><p><strong>Conclusions: </strong>HM3 appears to be a feasible intracorporeal long-term support option for selected pediatric patients in the post-HVAD era. Longer-term multicenter pediatric studies are needed to define durability, late complications, and optimal patient selection.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261480648"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CORVAD 4.0-assisted complex left main PCI in high-risk acute coronary syndrome with SCAI stage C cardiogenic shock: A case report.","authors":"Wenfang Zhu, Xiaofei Xie, Xiaoliang Han, Yuhong Chen, Liang Li, Guangcheng Sun, Shengxin Zuo, Jinpeng Xu","doi":"10.1177/03913988261479046","DOIUrl":"https://doi.org/10.1177/03913988261479046","url":null,"abstract":"<p><p>Temporary left ventricular support may be considered when cardiogenic shock and complex left main percutaneous coronary intervention (PCI) overlap, but the procedure depends on more than pump placement alone. We describe an 80-year-old man with high-risk acute coronary syndrome, ongoing ischemia for more than 12 h, SCAI stage C cardiogenic shock, left ventricular ejection fraction of 39%, and severe distal left main bifurcation disease in a left-dominant coronary system. Coronary angiography was performed through the right distal radial artery. Before femoral cannulation, the same radial access was used as an adjunct to obtain right iliofemoral angiographic information. After the femoral route was judged suitable, CORVAD 4.0 was implanted through the right femoral artery and provided approximately 2.1 L/min of support at level S5. PCI was performed through the right distal radial artery using a 7F EBU 3.0 guiding catheter. Intravascular ultrasound-guided DK-crush PCI was completed with final TIMI 3 flow. The device was kept in place for short-term intensive care support and removed once hemodynamics and end-organ perfusion had improved sufficiently, after fever and coagulase-negative staphylococcal blood culture growth raised concern for possible device- or access-related infection. Infection was subsequently controlled, and the patient was discharged after 11 days. This case illustrates a stepwise approach to temporary support, access assessment, complex PCI, and timely device removal when the clinical risk profile changes.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261479046"},"PeriodicalIF":1.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impella 5.5 as a bridge to dual-organ transplantation.","authors":"Wyatt Klass, Alex C Crane, George Chachati, Nicole Kunz, Ryan M Rivosecchi, Mohamed Abdullah, Raj Ramanan, Jonathan D Wolfe, Mary Keebler, Edward T Horn, David Kaczorowski, Gavin Hickey","doi":"10.1177/03913988261476499","DOIUrl":"https://doi.org/10.1177/03913988261476499","url":null,"abstract":"<p><p>The Impella 5.5 is increasingly utilized as temporary mechanical circulatory support to bridge patients in cardiogenic shock to heart transplantation. Patients listed for dual-organ transplantation may experience longer wait times than heart transplant alone. We aimed to evaluate the feasibility of Impella 5.5 as a bridge to dual-organ transplant. We performed a retrospective review of patients with cardiogenic shock supported with Impella 5.5 who subsequently underwent heart transplant or dual-organ transplant from 2021 to 2025. Dual-organ transplant included combined heart-kidney, heart-liver, and heart-lung transplants. Fifty-four total patients received Impella 5.5 bridge, for which six were dual-organ transplants. Blood type A was most common among both groups (heart transplant 39.6%, dual-organ transplant 66.7%). Median ages were 56 (IQR 46.5-61.2) for isolated heart transplants and 57.5 (IQR 37.5-62) years old for dual-organ transplants. All patients were SCAI class C or higher. Non-ischemic cardiomyopathy was the predominant etiology (heart transplant 100%, dual-organ transplant 83%). Dual organ transplant recipients underwent heart-kidney (<i>n</i> = 3), heart-lung (<i>n</i> = 1), or heart-liver (<i>n</i> = 2) transplants, with median Impella 5.5 support durations of 117, 19, and 42 days, respectively. This is compared to a median support duration of 14 days for isolated heart transplant recipients. Detailed baseline characteristics and post-transplant outcomes were similar across subgroups. Use of Impella 5.5 as a bridge to dual-organ transplants is feasible and safe in selected patients with cardiogenic shock with multi-organ failure. Further studies are needed to assess laboratory data, hemodynamics trajectories, and long-term survival outcomes in this population.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261476499"},"PeriodicalIF":1.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory role of permissive hypercapnia in inflammatory response and postoperative recovery: Evidence from laparoscopic surgery patients.","authors":"Jingjing Cui, Tao Jin, Bao Zhang","doi":"10.1177/03913988261467178","DOIUrl":"https://doi.org/10.1177/03913988261467178","url":null,"abstract":"<p><strong>Objective: </strong>As a lung-protective ventilation strategy, the regulatory effects of permissive hypercapnia on inflammatory mediators and clinical outcomes during laparoscopic surgery remain insufficiently clarified. This study investigated the impact of permissive hypercapnia on perioperative cytokine profiles and patient recovery in laparoscopic procedures.</p><p><strong>Methods: </strong>A retrospective analysis was conducted including 72 patients who received permissive hypercapnia ventilation (observation group) and 58 patients who underwent conventional ventilation (control group). Serum levels of interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-α), the oxygenation index (OI), and alveolar-arterial oxygen difference (P(A-a) O₂) were measured at multiple perioperative time points. Surgery-related indicators and postoperative complications were recorded.</p><p><strong>Results: </strong>At 24 h postoperatively, the observation group exhibited significantly lower IL-6 and TNF-α concentrations and higher IL-10 levels compared with the control group (<i>p</i> < 0.05). At 30 min after pneumoperitoneum and 24 h postoperatively, both OI and P(A-a) O₂ were higher in the observation group, whereas at the end of surgery they were slightly lower than in the control group (all <i>p</i> < 0.05). Extubation time (17.49 ± 3.62 min), hospital stay (5.67 ± 1.24 days), and complication rate (12.50%) were significantly improved in the observation group versus controls (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Permissive hypercapnia effectively modulates the balance of IL-6, IL-10, and TNF-α, enhances pulmonary oxygenation, attenuates perioperative inflammation, accelerates postoperative recovery, and reduces complications. These findings support its value as a lung-protective ventilation strategy in laparoscopic surgery.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261467178"},"PeriodicalIF":1.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward a conceptual framework for systemic effects of continuous renal replacement therapy in critical illness.","authors":"Yusuke Nishimura","doi":"10.1177/03913988261473824","DOIUrl":"https://doi.org/10.1177/03913988261473824","url":null,"abstract":"<p><p>Continuous renal replacement therapy (CRRT) is traditionally used for solute and fluid removal in critically ill patients with acute kidney injury. Emerging evidence suggests that CRRT may also influence systemic biological networks, including inflammation, vascular function, immunity, and metabolism. In sepsis and critical illness, these systems are dynamically dysregulated, involving fluctuating inflammatory mediators, endothelial alterations, immune dysfunction ranging from hyperinflammation to immunoparalysis, and metabolic reprogramming that varies with disease stage. We propose a conceptual framework in which CRRT modulates these interconnected processes. Beyond solute and cytokine removal, CRRT may affect the distribution of circulating mediators, attenuate concentration peaks, influence endothelial stability, and modulate immune and metabolic states, thereby contributing to systemic network regulation. However, CRRT has bidirectional effects. While it may help restore homeostasis by removing harmful mediators, it may also eliminate beneficial molecules and induce inflammatory or oxidative responses due to extracorporeal circulation. Therefore, its overall impact is likely context-dependent and influenced by treatment settings and patient condition. Although direct evidence for systemic reprogramming remains limited, this framework provides a basis for future research. Integrative biomarker-based and phenotyping approaches may support the development of individualized and adaptive CRRT strategies in critical care.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261473824"},"PeriodicalIF":1.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboxyhemoglobin as a biomarker of hemolysis: A systematic review and meta-analysis.","authors":"Stefano Fresilli, Alessandro Ruggiero, Alessandro Strumia, Letizia Perinati, Alessia Mattei, Marina Pieri, Giuseppe Pascarella, Massimiliano Carassiti, Luca Baldetti, Rita Cataldo, Lorenzo Schiavoni, Giovanni Landoni, Anna Mara Scandroglio, Alessandro Belletti","doi":"10.1177/03913988261474702","DOIUrl":"https://doi.org/10.1177/03913988261474702","url":null,"abstract":"<p><strong>Background: </strong>Hemolysis occurs frequently in patients requiring mechanical circulatory support (MCS) and is associated with worse outcomes. Carboxyhemoglobin (CO-Hb) has been suggested as a potential biomarker for detection of hemolysis and may be useful to guide clinicians' decisions to anticipate worsening hemolysis and prevent hemolysis-related adverse events.</p><p><strong>Methods: </strong>We performed a systematic review and meta-analysis of studies in PubMed, Embase, and Cochrane library with last search on September 2025 investigating the correlation between CO-Hb and hemolysis in patients requiring MCS. We included adult and pediatric patients undergoing support with MCS. Primary outcome was relationship between CO-Hb levels and hemolysis. Risk of bias was evaluated with Newcastle-Ottawa Scale tool. Hemolysis was collected through validated biomarkers or approved scores.</p><p><strong>Results: </strong>A total of 22 studies with 6566 patients were included. Eighteen studies investigated patients on ECMO, most of them on venovenous ECMO, and four studies on cardiopulmonary bypass. Four studies were eligible for quantitative synthesis and showed a positive correlation between pfHb and CO-Hb (fixed-effect model: <i>r</i> = 0.117, 95% confidence interval 0.086-0.147; <i>I</i>² = 21.7%; <i>p</i> < 0.0001). No studies reported data on timing of relative changes of CO-Hb and other hemolysis markers, detection of clinically relevant hemolysis, or start of ECLS.</p><p><strong>Conclusions: </strong>CO-Hb is weakly but significantly correlated with pfHb. There is lack of data on clinically relevant CO-Hb cutoffs or changes related to other hemolysis markers or clinical detection of hemolysis.</p><p><strong>Study registration: </strong>Registered on Prospero database under ID CRD420251121876, available from https://www.crd.york.ac.uk/PROSPERO/view/CRD420251121876.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261474702"},"PeriodicalIF":1.6,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of levosimendan before left ventricular assist device implantation in pediatric patients.","authors":"Abdulkadir Yılmaz, Sinan Sabit Kocabeyoglu, Ümit Kervan, Mehmet Karahan, Bekir Boğaçhan Akkaya, Enis Burak Gül, Burak Kasapoğlu, Zeki Çatav","doi":"10.1177/03913988261473042","DOIUrl":"https://doi.org/10.1177/03913988261473042","url":null,"abstract":"<p><strong>Objective: </strong>The pediatric patient group undergoing left ventricular assist device (LVAD) implantation is small and unique. Many efforts have been made to prolong survival. In our study, we aimed to evaluate the effects of levosimendan administration on postoperative outcomes in pediatric patients undergoing LVAD implantation.</p><p><strong>Methods: </strong>This retrospective single-center study included patients under 18 years of age who underwent LVAD implantation. Patients with INTERMACS class 1 were excluded from the study. Patients were divided into two groups: Group A (<i>n</i> = 14), who received levosimendan preoperatively in addition to standard inotropic therapy, and Group B (<i>n</i> = 17), who received standard inotropic therapy alone. Levosimendan was administered at a dose of 0.1 µg/kg/min for 72 h without a loading bolus. Primary outcomes were early right ventricular failure and in-hospital mortality. Secondary outcomes included the need for right ventricular assist, late right ventricular failure, and changes in organ function as assessed by liver and kidney function tests. Safety points for drug administration were defined as arrhythmia, hypotension, and sudden arrest.</p><p><strong>Results: </strong>Baseline characteristics (except LVEDD), ventricular function, and vasoactive inotropic scores were similar between the groups. No significant difference was observed in terms of early right ventricular failure, in-hospital mortality, or length of hospital stay. The rates of need for right ventricular assist and late right ventricular failure were comparable. Improvements in organ function were observed in both groups; significantly greater reductions in aspartate aminotransferase and alanine aminotransferase levels were recorded in the levosimendan group. No treatment-limiting side effects were observed.</p><p><strong>Conclusion: </strong>Preoperative levosimendan administration seems to be safe in pediatric LVAD candidates and is associated with improved end-organ function, although it has not demonstrated superiority over standard inotropic therapy in terms of preventing right ventricular failure or reducing mortality.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261473042"},"PeriodicalIF":1.6,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metal-based putty implant functionalized with copper nanoparticles for bone tissue regeneration.","authors":"Rethinam Senthil, Pelluru Geetha Sravanthy","doi":"10.1177/03913988261473524","DOIUrl":"https://doi.org/10.1177/03913988261473524","url":null,"abstract":"<p><p>This study developed and evaluated a sodium alginate/hydroxyapatite/copper nanoparticle (SA/HA/CuNPs) putty implant for bone tissue engineering. The green-synthesized CuNPs product was characterized by UV-Vis, FTIR, XRD, and FESEM analyses. The putty implant exhibited a porous structure, enhanced biomineralization, antioxidant activity, and strong antibacterial effects against gram-positive (22.4 ± 1.2 mm) and gram-negative (19.8 ± 1.0 mm) bacteria. Mechanical testing showed tensile and compressive strengths of 8.6 ± 0.5 MPa and 14.2 ± 0.8 MPa, respectively. Cytocompatibility studies demonstrated >86% cell viability and favorable live/dead staining results. Overall, the SA/HA/CuNP implant showed promising potential for bone regeneration applications.</p>","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"3913988261473524"},"PeriodicalIF":1.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148712552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}